

June 16, 2026: Compounds introduced or investigated in Kenneth A. Jacobson's lab (kennethj@niddk.nih.gov) at NIDDK (Molecular Recognition Section, MRS) or through collaborations. Orange compounds (110) are, were, or will soon be available commercially as research tools:

Abbreviation	Action (no. in paper)	Reference (year, vol:page) **
AB-MECA	selective A ₃ adenosine agonist, to radioiodinate (25)	JMC (1994) 37:636
Ac-APEC	A _{2A} adenosine agonist (3)	BC (2009) 20:1888
ADAC (MRS998)	selective A ₁ adenosine agonist (46)	BP (1987) 36:1697 JMC (2012) 55:8075
Alexa488-APEC	fluorescent A _{2A} AR agonist (isomer mixture) pure p-substituted isomer (MRS5206)	EJP (2008) 590:36 NI (2013) 63:42
APEC	selective A _{2A} adenosine agonist (6)* (1)	JMC (1994) 37:3614 PS (2009) 5:39
3'-Benzylamino-3'-deoxy-ATP	potent P2X agonist (25)	DDR (1994) 31:206
Benzyl-NECA	potent A ₃ adenosine agonist	MP (1994) 45:1101
Biotin-ADAC	A ₁ adenosine receptor agonist biotin conjugate	BP (1987) 36:1697
Biotin-TAC	M ₂ muscarinic antagonist (9)	BC (1992) 3:234
BTH₄	non-N-containing adenosine antagonist (7)	JMC (1996) 39:398
CI-IB-MECA (namodenoson, CF102)	selective A ₃ adenosine agonist (13) (12)	JMC (1994) 37:3614 BP (2020) 117:113934 NP (2017) 114:101 JMC (2002) 45:4471
CMB6446	selective A _{2B} adenosine antagonist	BMC (2003) 11:77
CSC	selective A _{2A} adenosine antagonist (28)	JMC (1993) 36:1333
DBXR	xanthine riboside as adenosine antagonist	JMC (1994) 37:4020
DBXRM	selective A ₃ adenosine agonist (8)	JMC (1994) 37:4020 JMC (2002) 45:4471
m-DITC-ADAC	selective A ₁ adenosine agonist affinity label (46)	JMC (1989) 32:1043
p-DITC-ADAC	selective A ₁ adenosine agonist affinity label (45)	JMC (1989) 32:1043
m-DITC-APEC	selective A _{2A} adenosine agonist affinity label (11)	JMR (1989) 2:170
p-DITC-APEC	selective A _{2A} adenosine agonist affinity label (12)	JMR (1989) 2:170
m-DITC-XAC	selective A ₁ adenosine antagonist affinity label (10)	JMC (1989) 32:1043
p-DITC-XAC	selective A ₁ adenosine antagonist affinity label (9)	JMC (1989) 32:1043
DPCPX (John Daly)	selective A ₁ adenosine antagonist (1) (15)	BP (1988) 37:3653 JMC (1988) 31:613
DU124182	selective A ₃ adenosine PAM (2-cPent-4-O-Ph)	MP (2002) 62:81
DU124183	selective A ₃ adenosine PAM (2-cPent-4-NH-Ph)	MP (2002) 62:81 MP (2003) 63:1021
DU124184	selective A ₃ adenosine PAM (2-cPent-4-NH-cPent)	MP (2002) 62:81
DU124482	selective A ₃ adenosine PAM (2-Ph-4-NH-cPent)	MP (2002) 62:81
FE@SUPPLY (MRS1532)	selective A ₃ adenosine antagonist (7)	JMC (1999) 42:706

FITC-ADAC	fluorescent A ₁ adenosine receptor agonist	BP (1987) 36:1697
FITC-APEC	fluorescent A _{2A} adenosine receptor agonist*	JF (1992) 2:217
GB49	selective A ₁ adenosine antagonist, CN ₂ -pyridine (8)	ACSMCL (2025) 16:1365
GB74	selective A ₁ adenosine antagonist, CN ₂ -pyridine (3)	ACSMCL (2025) 16:1365
GB75	selective A ₁ adenosine antagonist, CN ₂ -pyridine (9)	ACSMCL (2025) 16:1365
2-hexylthio-AMP	P2Y ₁₂ receptor agonist	BJP (1996) 118:1959
I-AB-MECA	A ₃ adenosine agonist (26)	JMC (1994) 37:636
		MP (1994) 45:978
IB-MECA	selective A ₃ adenosine agonist (16)	JMC (1994) 37:636
	(piclidenoson, CF101)	NP (2017) 114:101
	(11)	JMC (2002) 45:4471
IB-MECA prodrug	selective A ₃ adenosine agonist diester (38)	JMC (1995) 38:1720
IB-MECA prodrugs	selective A ₃ adenosine agonist diesters (5-7)	CCC (2006) 71:912
ICBM (MRS1163)	selective A ₃ adenosine agonist affinity label (4)	BBRC (1994) 203:570
		PS (2024) 20:35
[¹²⁵I]-ZM241,385	selective A _{2A} adenosine antagonist radioligand	MP (1996) 48:970
[¹²⁵I]-AB-MECA	A ₃ adenosine agonist radioligand	ACSPT (2022) 5(8):625
		MP (1994) 45:978
[¹²⁵I]-azido-PAPA-APEC	A _{2A} adenosine agonist photoaffinity radioligand	MP (1991) 39:130
LC260	selective A ₃ adenosine agonist, 2-triazole (15)	JMC (2006) 49:7373
LJ529 CHEMBL200732	selective A ₃ agonist (4'-S-Cl-IB-MECA, 3)	JMC (2003) 46:3775
	(39a)	JMC (2006) 49:273
	(6)	JMC (2007) 50:3159
LJ1256	selective A ₃ antagonist (4'-S, nucleoside, 7)	BMCL (2006) 16:596
LJ1258 (MRS3884)	selective A ₃ agonist (4'-S-IB-MECA, 5h)	
	CHEMBL522152	BMC (2009) 17:8003
LJ1351 (MRS3973)	hA ₃ receptor antagonist (3-Br-Bn, <i>N,N</i> -diMe, 6c)	BMCL (2008) 18:1612
LJ1888 (LJ1251, MRS3820)	selective A ₃ adenosine antagonist truncat. (3-I) (6e)	JMC (2008) 51:6609
	(9d)	JMC (2007) 50:3159
	(3a)	JMC (2017) 60:7459
LJ2126 (MRS5292)	hA ₃ receptor antagonist/A _{2A} agonist (4a)	JMC (2012) 55:342
LJ2163 (MRS5450)	hA ₃ receptor antagonist (6a)	JMC (2021) 64:12525
LJ2521 (MRS5584)	hA ₃ receptor antagonist (6c)	JMC (2021) 64:12525
LJ2698 (MRS5014, FM101)	hA ₃ receptor antagonist, truncat. (3-Cl) (9b)	JMC (2007) 50:3159
	(3b)	JMC (2017) 60:7459
	(6c)	JMC (2008) 51:6609
LJ3429 (MRS7002)	selective A ₃ seleno-adenosine agonist (3p)	JMC (2017) 60:3422
LJ3440 (MRS5742) CHEMBL4088081	selective A ₃ agonist, 4'-Se-IB-MECA, (3d)	JMC (2017) 60:3422
LJ4378 (MRS5281)	truncated hA ₃ receptor antagonist/A _{2A} agonist (4g)	JMC (2012) 55:342
	(4a)	ACSMCL (2010) 1:516
LJ4517 (MRS7049)	hA _{2A} receptor nucleoside antagonist (2)	JMC (2022) 65(8):6325
cLNA-adenosine	first carbocyclic "locked" nucleoside (23)	OL (2003) 5:1665
LUF5999	weak A ₃ adenosine allosteric modulator	BP (2011) 82:658

LUF6000	selective A ₃ adenosine allosteric enhancer (43) (4)	JMC (2006) 49:3354 ACSPT (2022) 5(8):625
metrifudil	mixed A ₁ /A ₃ adenosine agonist, 2-Me-Bn (11)	JMC (2005) 48:1745
MG325	selective A ₁ adenosine agonist, nonnucleoside (27)	ACSCN (2021) 12:3410
MMPD	A ₁ adenosine partial agonist PET ligand (22b)	JMC (2018) 61:9966
MRS512	A ₁ /A ₃ adenosine antagonist (xanthine, 21)	JMC (1994) 37: 3373
MRS541	IB-Ado, A ₃ low efficacy agonist (4) (7a)	JMC (2002) 45:4471 JMC (2000) 43:2196
MRS542	A ₃ adenosine low efficacy agonist/antagonist (5)	JMC (2002) 45:4471
MRS582	carbocyclic IB-MECA, A ₃ adenosine agonist (3)	JMC (2000) 43:2196
MRS923	selective flavonoid A ₃ adenosine antagonist (6)	JMC (1996) 39:2293
MRS928	selective flavonoid A ₃ adenosine antagonist (2)	JMC (1996) 39:2293
MRS1041	selective flavonoid A ₃ adenosine antagonist (3a)	JMC (1996) 39:2293
MRS1042	selective flavonoid A ₃ adenosine antagonist (4)	JMC (1996) 39:2293
MRS1062	selective flavonoid A ₃ adenosine antagonist (16)	JMC (1996) 39:2293
MRS1065	selective flavonoid A ₃ adenosine antagonist (19)	JMC (1996) 39:2293
MRS1066	selective flavonoid A ₃ adenosine antagonist (20)	JMC (1996) 39:2293
MRS1067	selective flavonoid A ₃ adenosine antagonist (11e)	JMC (1996) 39:2293
MRS1086	selective flavonoid A ₃ adenosine antagonist (8)	JMC (1996) 39:2293
MRS1088	selective flavonoid A ₃ adenosine antagonist (11d)	JMC (1996) 39:2293
MRS1093	selective flavonoid A ₃ adenosine antagonist (3b)	JMC (1996) 39:2293
MRS1097	selective hA ₃ adenosine antagonist (DHP, 1)	JMC (1997) 40:2596
MRS1132	selective flavonoid A ₃ adenosine antagonist (11b)	JMC (1996) 39:2293
MRS1177	selective hA ₃ adenosine antagonist (10)	JMC (1996) 39:4142
MRS1178	A _{2B} adenosine antagonist (39)	JMC (1998) 41:2835
MRS1186	selective hA ₃ adenosine antagonist (3)	JMC (1996) 39:4142
MRS1191	selective hA ₃ adenosine antagonist (DHP, 2)	JMC (1997) 40:2596 NP (2017) 114:101
MRS1220	selective hA ₃ adenosine antagonist (12)	JMC (1996) 39:4142 PS (2021) 17:737 ACSPT (2023) 6:1266
MRS1292	selective A ₃ adenosine nucl. antagonist (spirane, 14)	JMC (2002) 45:4471
MRS1334	selective hA ₃ adenosine antagonist (DHP, 24g)	JMC (1997) 40:2596 PS (2021) 17:737
MRS1458	irreversible (sulfonyl-F) A ₃ antagonist (19)	BC (1999) 10:667
MRS1476	selective hA ₃ adenosine antagonist (6) (38)	JMC (1999) 42:706 JMC (1998) 41:3186
MRS1477	allosteric enhancer of TRPV1 channels (DHP)	JPET (2012) 340:152
MRS1486	selective A ₃ adenosine antagonist (45)	JMC (1998) 41:3186
MRS1505	selective A ₃ adenosine antagonist (44)	JMC (1998) 41:3186
MRS1523	selective A ₃ adenosine antagonist (4) (39b)	JMC (1999) 42:706 JMC (1998) 41:3186 PS (2021) 17:737 NP (2017) 114:101
MRS1595	selective A _{2B} adenosine antagonist (14)	DDR (1999) 47:178
MRS1649	permanently charged A ₃ antagonist (11)	JMC (1999) 42:4232

aristeromycin	carbocyclic-adenosine (5b), A _{2A} agonist	JMC (2000) 43:2196
MRS1655	(N)-methanocarba-adenosine (5c), A ₃ agonist	JMC (2000) 43:2196
MRS1656	(S)-methanocarba-adenosine (5d), racemic	JMC (2000) 43:2196
MRS1667	prodrug (24) of permanently charged A ₃ antagonist	JMC (1999) 42:4232
MRS1706	selective A _{2B} adenosine antagonist (20)	JMC (2000) 43:1165
MRS1740	bivalent A ₁ /A ₃ adenosine agonist conjugate	JBC (2000) 275:30272
MRS1741	bivalent A ₁ /A ₃ adenosine agonist conjugate	JBC (2000) 275:30272
MRS1743	A ₃ adenosine low efficacy agonist (17)	JMC (2002) 45:4471
	(7c)	JMC (2000) 43:2196
MRS1748	A _{2B} adenosine antagonist, long residence time (17)	BP (2022) 200:115027
MRS1754	selective A _{2B} adenosine antagonist (27)	JMC (2000) 43:1165
[³H]MRS1754	selective A _{2B} adenosine antagonist radioligand	BP (2001) 61:657
MRS1758	A _{2B} adenosine antagonist (18)	BP (2022) 200:115027
MRS1760	A ₃ adenosine low efficacy agonist/antagonist (18)	JMC (2002) 45:4471
	(9c)	JMC (2000) 43:2196
MRS1761	2-Cl-(N)-methanocarba-N ⁶ -cyclopentyl-Ado (8c)	JMC (2000) 43:2196
MRS1765	selective A _{2B} adenosine antagonist (33)	JMC (2000) 43:1165
MRS1781	(N)-methanocarba-N ⁶ -cyclopentyl-Ado (6c)	JMC (2000) 43:2196
MRS1845	inhibitor of store-operated calcium channels	BP (2003) 65:329
MRS1873	mixed A _{1/3} adenosine agonist (21)	JMC (2019) 62:1502
	(12)	JMC (2016) 59:11006
	(15)	JMC (2002) 45:4471
	(4)	BMCL (2001) 11:1333
MRS1878	mixed A _{2A/2B} adenosine antagonist (22)	BP (2022) 200:115027
MRS1898	selective A ₃ adenosine agonist (5)	JMC (2005) 48:1745
[¹²⁵I]MRS1898	selective A ₃ adenosine agonist radioligand	PS (2009) 5:31
MRS1940	(N)-methanocarba-NECA (5), potent AR agonist	BMCL (2001) 11:1333
MRS1941	(N)-methanocarba-guanosine (8), weak A ₃ ligand	BMCL (2001) 11:2295
MRS1942	(N)-methanocarba-NBTI, ENT1 inhibitor	OL (2001) 3:597
MRS1947	N ⁶ -Me-(N)-methanocarba-inosine (13), weak at A ₃	JMC (2016) 59:11006
MRS1957	(N)-methanocarba-inosine (5), weak at A ₃	BMCL (2001) 11:2295
MRS1997	(N)-methanocarba-MECI (6), weak A ₃ agonist	BMCL (2001) 11: 2295
MRS2055	P2Y ₁₂ agonist, 2-(5-hexenylthio) (17b)	JMC (2002) 45:4057
		DDR (2000) 49:253
MRS2154	P2X2 enhancer, dihydropyridine deriv. (5a)	JANS (2000) 81:152
MRS2159	selective P2X1 antagonist, pyridoxal deriv. (4)	JMC (2001) 44:340
		DDR (2001) 53:281
		(10)
MRS2160	P2X2 antagonist, pyridoxal deriv. (38)	DDR (1998) 45:52
		JMC (2002) 45:4057
		(15)
MRS2179	selective P2Y ₁ deoxyribose antagonist (9)	DDR (1998) 45:52
	(2)	JMC (1998) 41:183
		JMC (1999) 42:1625
MRS2191	P2X2 antagonist, pyridoxal deriv. (42)	JMC (2002) 45:4057
		DDR (2001) 53:281
		(20)
MRS2209	P2Y ₁ antagonist, N ⁶ -Me-2',5'-bisphosphate	DDR (1998) 45:52
		DDR (2000) 49:253

MRS2210	nonnucleotide P2Y ₁ antagonist, related to PPADS	DDR (2002) 57:173
MRS2211	selective, nonnucleotide P2Y ₁₃ antagonist	BP (2005) 70:266
MRS2216	selective P2Y ₁ deoxyribose antagonist (6)	JMC (1999) 42:1625
	(5a)	DDR (2000) 49:253
MRS2217	P2Y ₁ antagonist, N ⁶ -Me-2-MeS-3',5'-bisphos. (5b)	DDR (2000) 49:253
MRS2219	P2X ₁ allosteric enhancer (2)	JMC (1998) 41:2201
MRS2220	P2X ₁ antagonist (3)	JMC (1998) 41:2201
MRS2231	weak P2Y ₁ deoxyribose antagonist (6)	JCIM (2017) 57:3104
MRS2239	selective P2Y ₁ deoxyribose antagonist (15)	JCIM (2017) 57:3104
MRS2242	selective P2Y ₁ deoxyribose partial agonist (13)	JMC (1999) 42:1625
MRS2248	P2Y ₁ antagonist, N ⁶ -Me-2-NH ₂ -3',5'-bisphos (5c)	DDR (2000) 49:253
MRS2255	P2Y ₁ bisphosphate anhydrohexitol agonist (36)	JMC (1999) 42:1625
MRS2257	P2X ₁ , P2X ₂ , P2X ₃ , P2X ₄ antag., pyridoxal der. (9)	JMC (2001) 44:340
		DDR (2001) 53:281
MRS2266	P2Y ₁ (S)-methanocarba bisphos. partial agonist (5)	JMC (2000) 43:829
MRS2267	P2Y ₁ antagonist, N ⁶ -Me-3',5'-bisphosphate	DDR (2000) 49:253
MRS2268	P2Y ₁ (N)-methanocarba bisphosphate agonist (4a)	JMC (2000) 43:829
	(17)	JCIM (2017) 57:3104
MRS2269	P2Y ₁ anhydrohexitol antagonist, N ⁶ -Me (9)	DDR (2001) 53:281
MRS2275	selective P2Y ₁ methanocarba antagonist (19)	JCIM (2017) 57:3104
MRS2277	P2Y ₁ acyclic bisphosphate antagonist (37)	JCIM (2017) 57:3104
MRS2279	selective P2Y ₁ methanocarba antagonist (5)	JMC (2003) 46:4974
MRS2283	P2Y ₁ anhydrohexitol antagonist (32)	JCIM (2017) 57:3104
	(12)	BMC (2004) 12:5619
MRS2284	P2X ₁ antag., pyridoxal phosphonate der. (5)	JMC (2001) 44:340
		DDR (2001) 53:281
MRS2285	P2X ₁ , P2X ₂ , P2X ₃ antag., pyridoxal der. (7)	JMC (2001) 44:340
MRS2286	selective P2Y ₁ acyclic bisphosphate antagonist (12)	JMC (2002) 45:5694
	(11)	DDR (2001) 53:281
MRS2289	selective P2Y ₁ c-Pr bisphosphate antagonist (17)	JMC (2001) 44:3092
MRS2295	selective P2Y ₁ alkene bisphosphate antagonist (15)	JMC (2001) 44:3092
MRS2297	selective P2Y ₁ antagonist (13)	JMC (2002) 45:5694
MRS2298	selective P2Y ₁ acyclic bisphosphate antagonist	BP (2004) 68:1995
	(14)	JMC (2002) 45:5694
MRS2303	P2Y ₁ acyclic bisphosphate antagonist (35)	JCIM (2017) 57:3104
MRS2304	(N)-methanocarba-AMP, no effect at P2Y ₁ (4a)	JMC (2002) 45:208
MRS2306	selective P2X ₇ antagonist (2)	BMCL (2008) 18:571
MRS2312	(S)-methanocarba-ATP, weak P2Y ₁ /P2Y ₂ ag. (8a)	JMC (2002) 45:208
MRS2339	cardiac P2X ₄ agonist (3)	JMC (2010) 53:2562
	2-Cl-(N)-methanocarba-AMP, weak P2Y ₁ ag. (13a)	JMC (2002) 45:2090
MRS2340	(N)-methanocarba-ATP, P2X, P2Y agonist	DDR (2004) 61:227
	(6a)	JMC (2002) 45:2090
MRS2341	(N)-methanocarba-UTP, P2Y ₂ /P2Y ₄ agonist (5a)	JMC (2002) 45:208
MRS2343	2-Cl-N ⁶ -Me-(N)-methanocarba-ATP,	
	P2Y ₁ agonist (15a)	JMC (2002) 45:2090
MRS2347	2-MeS-(N)-methanocarba-AMP, weak P2Y ₁ ag. (10a)	JMC (2002) 45:2090

MRS2352	β,γ -me-(N)-methanocarba-ATP, P2Y ₁ agonist (17a)	JMC (2002) 45:2090
MRS2365	selective P2Y ₁ agonist (2-MeS-ADP analogue, 9a)	JMC (2002) 45:2090 JPET (2004) 311:1038 JTH (2006) 4:861
MRS2367	2-Cl-(N)-methanocarba-ATP, P2Y ₁ agonist (12a)	JMC (2002) 45:2090
MRS2371	N ⁶ -Me-methanocarba-ATP, P2Y ₁ ag. (14a)	JMC (2002) 45:2090
MRS2395	P2Y ₁₂ antagonist (moderate potency) (26)	JMC (2002) 45:5694
MRS2427	selective P2X ₇ antagonist (16)	BMCL (2008) 18:571
MRS2457	TNA-bisphosphate, P2Y ₁ antagonist (9)	BMC (2004) 12:5619
MRS2488	TNA-triphosphate, P2Y ₂ agonist (13)	BMC (2004) 12:5619
MRS2496	selective P2Y ₁ antagonist	BP (2004) 68:1995
MRS2481	blocker of Ca ²⁺ channel formed by amyloid pept.	PNAS (2009) 106:3348
MRS2500	selective P2Y ₁ methanocarba antagonist (12)	JMC (2003) 46:4974 Nat (2015) 520:317 JCIM (2017) 57:3104
MRS2503	selective P2Y ₁ methanocarba antagonist (26)	JCIM (2017) 57:3104
MRS2519	selective P2Y ₁ methanocarba antagonist (22)	JCIM (2017) 57:3104
MRS2520	selective P2Y ₁ methanocarba antagonist (20)	JCIM (2017) 57:3104
MRS2540	selective P2X ₇ antagonist	EER (2010) 91:425
MRS2567	Selective P2Y ₆ antagonist	BP (2004) 67:1763
MRS2575	Selective P2Y ₆ antagonist	BP (2004) 67:1763
MRS2576	nonselective, irrev. P2Y receptor antagonist	BP (2004) 67:1763
MRS2577	irrev. P2Y ₄ /P2Y ₆ receptor antagonist	BP (2004) 67:1763
MRS2578	selective P2Y ₆ antagonist (irreversible, insurmountable)	BP (2004) 67:1763 BMCL (2015) 25:4733
MRS2584	inactive at P2Y ₁₄ R	BMC (2004) 12:5619
MRS2603	P2Y ₁ carbocyclic-LNA antagonist (21)	BP (2005) 70:266
MRS2608	P2Y ₁ /P2Y ₁₃ antagonist, nonnucleotide	JMC (2007) 50:3229
MRS2611	precursor of radiolabeled P2Y ₁ antagonist (14)	JCIM (2017) 57:3104
MRS2611	selective P2Y ₁ methanocarba antagonist (27)	JMC (2005) 48:8108
MRS2633	P2Y ₆ (S)-methanocarba 2'-d agonist (10)	JMC (2010) 53:4488
	(6)	MCC (2017) 8:1897
	(12)	JMC (2005) 48:8108
MRS2637	2'-d-UDP, P2Y ₆ agonist (3)	JMC (2006) 49:5532
MRS2666	P2Y ₆ 2-OBH agonist (19)	JMC (2007) 50:2030
MRS2670	selective P2Y ₁₄ agonist (4-thio) (13)	JMC (2007) 50:2030
MRS2690	selective P2Y ₁₄ agonist (2-thio) (15)	JMC (2010) 53:471
	(2)	BMCL (2015) 25:4733
	(3)	JMC (2006) 49:5532
MRS2693	selective P2Y ₆ agonist (32)	JMC (2006) 49:5532
MRS2695	selective P2Y ₆ agonist, 2-thio (20)	JMC (2006) 49:5532
MRS2638	selective P2Y ₆ agonist, 4-thio (21)	JMC (2006) 49:5532
MRS2647	selective P2Y ₆ agonist, 4-allylthio (24)	JMC (2006) 49:5532
MRS2686	selective P2Y ₆ agonist, 4-ethylthio (23)	JMC (2006) 49:5532
MRS2698	selective P2Y ₂ agonist (8)	JMC (2007) 50:1166
MRS2703	caged P2Y _{1/12/13} agonist (4)	BP (2008) 75:1341
MRS2767	5'-amino-UDP, P2Y ₆ agonist (11)	BMC (2008) 16:6319

MRS2768	selective P2Y ₂ agonist (30)	BMC (2008) 16:6319
MRS2774	potent P2Y ₆ agonist, Up ₃ U (38)	BMC (2008) 16:6319
MRS2775	cardiac P2X ₄ agonist (4)	JMC (2010) 53:2562
MRS2782	potent and selective P2Y ₆ agonist, α,β -me-UDP (9)	BMC (2008) 16:6319
MRS2795	P2Y ₆ receptor agonist, (S)-methanocarba-UDP (13)	MCC (2017) 8:1897
MRS2801	putative allosteric P2Y ₂ receptor partial agonist (7)	BMCL (2009) 19:3002
MRS2802	selective P2Y ₁₄ agonist (12)	JMC (2010) 53:471
MRS2804	P2Y ₆ receptor agonist (8)	MCC (2017) 8:1897
MRS2815	mixed P2Y ₆ and P2Y ₁₄ agonist (11) (15)	JMC (2010) 53:4488 BMCL (2021) 45:128137
MRS2816	carboxylic P2Y ₁ antagonist (8)	BC (2010) 21:1190
MRS2821	dendrimer-conjugated P2Y ₁₄ agonist (9)	BC (2009) 20:1650
MRS2829	precursor of radioiodinated P2Y ₁ antagonist (6)	PR (2010) 62:344
MRS2892	amine-functionalized P2Y ₁₄ agonist (3a)	BC (2009) 20:1650
MRS2900	selective P2Y ₁ methanocarba antagonist (29)	JCIM (2017) 57:3104
MRS2905	selective P2Y ₁₄ agonist (11)	JMC (2010) 53:471 CB (2025) 8:1816
MRS2907	selective P2Y ₁₄ agonist (18)	JMC (2010) 53:471
MRS2920	potent P2Y ₆ agonist, N ⁴ -Me-O-Cp ₃ -glucose (32)	JMC (2010) 53:4488
MRS2925	cardiac P2X ₄ agonist	JMC (2010) 53:2562
MRS2927	slightly selective P2Y ₄ agonist (34)	JMC (2011) 54:4018
MRS2935	cardiac P2X ₄ agonist (9)	JMC (2010) 53:2562
MRS2950	nonnucleotide P2Y ₁ receptor antagonist (2a)	BMC (2012) 20:5254
MRS2957	potent and selective P2Y ₆ agonist (23) (12)	JMC (2010) 53:4488 BMCL (2015) 25:4733
MRS2964	potent and selective P2Y ₆ agonist (15) (10)	JMC (2010) 53:4488 MCC (2017) 8:1897
MRS2973	pan-agonist of P2Y ₂ , P2Y ₄ and P2Y ₆ (11)	JMC (2011) 54:4018
MRS2976	potent P2Y ₄ agonist; P2Y ₆ agonist (14)	JMC (2011) 54:4018
MRS2978	in vivo, cardiac P2X ₄ agonist	JMC (2013) 56:902 PS (2020) 16:61
MRS3210	carbocyclic-LNA adenosine (23)	OL (2003) 5:1665
MRS3342	2-I-N ⁶ -Me LNA adenosine (19)	BMC (2004) 12:5619
MRS3366	orthogonal A _{2A} adenosine agonist for neoceptor	TIPS (2007) 28:111
MRS3474	putative allosteric P2Y ₁ receptor NAM (20)	OBC (2005) 3:2016
MRS3481 (LJ1254)	orthogonal A ₃ adenosine agonist for neoceptor	JMC (2006) 49:2689
MRS3489	selective A ₃ adenosine agonist, 2,2-di-Ph-Et (34)	JMC (2005) 48:1745
MRS3534	A _{2B} adenosine receptor agonist, 6-H (17)	JMC (2007) 50:1810 BP (2014) 90:297
MRS3554	selective A ₃ adenosine agonist, 2,5-di-Cl-Bn (20)	JMC (2005) 48:1745
MRS3558 (CF502)	selective A ₃ adenosine agonist, 3-Cl-Bn (18)	JMC (2005) 48:1745
MRS3581	selective Br-76 A ₃ adenosine agonist	NMB (2009) 36:3
MRS3602	selective A ₃ adenosine agonist, 2,5-di-MeO-Bn (26)	JMC (2005) 48:1745
MRS3609	selective A ₃ adenosine agonist (35)	JMC (2005) 48:1745
MRS3611	selective A ₃ adenosine agonist (36)	JMC (2005) 48:1745
MRS3630	mixed A ₁ and A ₃ adenosine agonist (2)	JMC (2005) 48:8103

MRS3638	mixed A ₁ and A ₃ adenosine agonist (3)	JMC (2005) 48:8103
MRS3642 (LJ1256)	selective A ₃ adenosine antagonist (7)	BMCL (2006) 16:596
MRS3706	mixed A ₁ and A ₃ adenosine agonist (1)	JMC (2005) 48:8103
MRS3771	selective A ₃ adenosine antagonist, nucleoside (6)	BMCL (2006) 16:596
	(3)	BMCL (2008) 16:8546
MRS3775	selective A ₃ adenosine antagonist (21, CAY 10498)	JMC (2005) 48:4910
MRS3777	selective A ₃ adenosine antagonist (22)	JMC (2005) 48:4910
MRS3854	A _{2B} adenosine receptor agonist (24, Br-isomer)	JMC (2007) 50:1810
MRS3997	A _{2B} adenosine agonist (28)	JMC (2007) 50:1810
MRS4061	moderately selective P2Y ₄ agonist (15)	JMC (2011) 54:4018
MRS4062	moderately selective P2Y ₄ agonist (16)	JMC (2011) 54:4018
MRS4063	clickable P2Y ₆ receptor agonist (15)	MCC (2013) 4:1156
MRS4074	in vivo, cardiac P2X ₄ agonist (8)	JMC (2013) 56:902
MRS4084	in vivo, cardiac P2X ₄ agonist (7)	JMC (2013) 56:902
MRS4129	selective fluorescent (AF488) P2Y ₆ R agonist (16)	MCC (2013) 4:1156
MRS4141	selective P2Y ₆ receptor agonist (10)	MCC (2013) 4:1156
MRS4142	selective P2Y ₆ receptor agonist (12)	MCC (2013) 4:1156
MRS4149	alkyne-functionalized P2Y ₁₄ antagonist (22)	ACSCB (2014) 9:2833
	(3)	ACSML (2020) 11:1281
MRS4160	clickable P2Y _{2/4/6} receptor agonist (26)	JMC (2014) 57:3874
MRS4162	fluorescent (Bodipy) P2Y _{2/4/6} receptor agonist (28)	JMC (2014) 57:3874
MRS4165	P2Y ₆ receptor agonist (9a)	MCC (2017) 8:1897
	Nucleotide CD73 inhibitor, N ⁴ -OMe (9a)	JMC (2019) 62:3677
MRS4166	P2Y ₆ receptor agonist (9b)	MCC (2017) 8:1897
	Nucleotide CD73 inhibitor, N ⁴ -OBn (9b)	JMC (2019) 62:3677
MRS4174	fluorescent (AF488) P2Y ₁₄ receptor antagonist (30)	ACSCB (2014) 9:2833
MRS4183	fluorescent (Bodipy) P2Y ₁₄ receptor agonist (11)	BMCL (2015) 25:4733
MRS4202	adenosine kinase inhibitor (34)	JMC (2016) 59:6860
MRS4203	adenosine kinase inhibitor (38a)	JMC (2016) 59:6860
MRS4217	selective P2Y ₁₄ antagonist (65)	JMC (2016) 59:6149
MRS4322	mixed A _{1/3} adenosine agonist (8a)	RSCA (2021) 11:27369
		PS (2020) 16:543
MRS4380	adenosine kinase inhibitor (55)	JMC (2016) 59:6860
MRS4383	P2Y ₆ receptor (S)-methanocarba agonist (18)	MCC (2017) 8:1897
	(7)	JMC (2010) 53:4488
	(6)	BMCL (2021) 45:128137
MRS4387	P2Y ₆ receptor dinucleotide agonist (24)	MCC (2017) 8:1897
MRS4458	selective P2Y ₁₄ antagonist (20)	JMC (2018) 61:4860
MRS4478	selective P2Y ₁₄ antagonist (30)	JMC (2018) 61:4860
MRS4519	P2Y ₁₄ receptor antagonist, minimal deriv. (2)	ACSML (2020) 11:1281
	(19)	ACSPTS (2025) 8:3126
MRS4549	potent P2Y ₆ receptor agonist (17)	BMCL (2021) 45:128137
MRS4552	nucleotide CD73 inhibitor, 3-Me-N ⁴ -OBn (9h)	JMC (2019) 62:3677
(JMS0414)		
MRS4553	nucleotide CD73 inhibitor, 3-Et-N ⁴ -OBn (9i)	JMC (2019) 62:3677
MRS4554	P2Y ₆ receptor agonist (25)	BMCL (2021) 45:128137

MRS4564	potent P2Y ₆ receptor agonist (18)	BMCL (2021) 45:128137
MRS4567	P2Y ₆ receptor agonist (28)	BMCL (2021) 45:128137
MRS4571	P2Y ₁₄ receptor antagonist, PEG-linked (12)	JMC (2020) 63:9563
MRS4574	P2Y ₁₄ receptor antagonist, <i>N</i> -Pr (6b)	JMC (2020) 63:9563
MRS4575	P2Y ₁₄ receptor antagonist, <i>N</i> -Boc (10)	JMC (2020) 63:9563
MRS4576	P2Y ₁₄ receptor antagonist, <i>N</i> -Me (5)	JMC (2020) 63:9563
MRS4577	P2Y ₁₄ receptor antagonist, <i>N</i> -hexyl (7b)	JMC (2020) 63:9563
MRS4578	P2Y ₁₄ receptor antagonist, <i>N</i> -propargyl (6a)	JMC (2020) 63:9563
MRS4589	(<i>S</i>)-methanocarba-GTP (4a)	BIOM (2022) 12:584
MRS4590	(<i>N</i>)-methanocarba-GTP (4d)	BIOM (2022) 12:584
MRS4591	(<i>S</i>)-methanocarba-GMP-PCP (4b)	BIOM (2022) 12:584
MRS4596	P2X ₄ R antagonist (21c , neutral; 22c , Na ⁺ salt)	JMC (2022) 65:13967
MRS4598	nucleotide CD73 inhibitor (16)	JMC (2022) 65:2409
MRS4602	nucleotide CD73 inhibitor (21)	JMC (2022) 65:2409
MRS4608	P2Y ₁₄ receptor antagonist, quinuclidine (17)	JMC (2020) 63:9563
MRS4616	P2Y ₁₄ receptor antagonist, quaternary N (21)	JMC (2020) 63:9563
MRS4620	nucleotide CD73 inhibitor (18)	JMC (2022) 65:2409
MRS4622	Nucleotide CD73 inhibitor (20)	JMC (2022) 65:2409
MRS4625	P2Y ₁₄ receptor antagonist (4)	ACSML (2020) 11:1281
	(8)	JMC (2020) 63:9563
MRS4632	Nucleotide CD73 inhibitor, clickable (12)	ANG (2026) 2026:e22758
MRS4639	P2Y ₁₄ receptor antagonist (8)	JMC (2022) 65:3434
MRS4640	P2Y ₁₄ receptor antagonist (7)	JMC (2022) 65:3434
MRS4647	Nucleotide CD73 inhibitor, Alexa488 label (12)	unpublished
MRS4648	Nucleotide CD73 inhibitor with ¹⁸ F label (2)	ANG (2026) 2026:e22758
MRS4654	P2Y ₁₄ receptor antagonist (32)	JMC (2021) 64:5099
	(150)	JMC (2022) 65:3434
MRS4656	P2Y ₆ receptor antagonist (16)	BMCL (2021) 41:128008
	(6)	BMCL (2022) 75:128981
	(17)	Cells (2024) 13:1366
MRS4666	P2Y ₆ receptor antagonist (10)	Cells (2024) 13:1366
MRS4693	P2Y ₁₄ receptor antagonist (bridged <i>c</i> -Pr, 9)	JMC (2022) 65:3434
MRS4695	P2Y ₆ receptor antagonist (7)	BMCL (2021) 41:128008
	(4)	BMCL (2022) 75:128981
MRS4706	P2Y ₆ receptor antagonist (14)	BMCL (2021) 41:128008
MRS4709	P2Y ₁₄ R antag. ester prodrug of MRS4654 (151)	JMC (2022) 65:3434
MRS4719	P2X ₄ receptor antagonist (21u)	JMC (2022) 5:13967
MRS4738	P2Y ₁₄ receptor antagonist (15)	JMC (2022) 65:3434
	(2b)	JMC (2023) 66:9076
MRS4741	P2Y ₁₄ R antag. ester prodrug of MRS4625 (37c)	JMC (2021) 64:5099
MRS4742	P2Y ₁₄ receptor antag. (16), MRS4738 enantiomer	JMC (2022) 65:3434
MRS4745	P2Y ₁₄ receptor antagonist (lactam, 22)	JMC (2022) 65:3434
MRS4746	P2Y ₁₄ receptor antagonist (lactam, 23)	JMC (2022) 65:3434
MRS4748	P2Y ₁₄ receptor antagonist (38)	JMC (2022) 65:3434
MRS4757	P2Y ₁₄ R antag. ester prodrug of MRS4745 (144)	JMC (2022) 65:3434
MRS4758	P2Y ₁₄ R antag. ester prodrug of MRS4746 (145)	JMC (2022) 65:3434

MRS4759	mixed A ₃ agonist/P2Y ₁₄ receptor antagonist	ACSPT (2022), 5:973
MRS4774	P2Y ₆ receptor antagonist (8)	BMCL (2021) 41:128008
MRS4773	P2Y ₆ receptor antagonist (9)	BMCL (2021) 41:128008
MRS4779	P2Y ₁₄ R antag. ester prodrug (141) of MRS4738 (15) (63)	JMC (2022) 65:3434 JMC (2023), 66(13):9076
MRS4799	P2Y ₁₄ R antag. (20), amide of MRS4742 (16)	JMC (2022) 65:3434
MRS4806	P2Y ₁₄ R antag. ester prodrug of MRS4799 (146)	JMC (2022) 65:3434
MRS4814	P2Y ₁₄ R antag. carbamate prodrug of MRS4738 (142)	JMC (2022) 65:3434
MRS4815	P2Y ₁₄ R antag. double prodrug of MRS4738 (143) (64)	JMC (2022) 65:3434M JMC (2023), 66(13):9076
MRS4816	P2Y ₆ receptor antagonist (16)	Cells (2024) 13:1366
MRS4817	P2Y ₆ receptor antagonist (24)	BMCL (2022) 75:128981
MRS4820	P2Y ₁₄ receptor antagonist (8)	JMC (2023), 66(13):9076
MRS4825	P2Y ₁₄ receptor antagonist (17)	JMC (2023), 66(13):9076
MRS4830	P2Y ₆ receptor antagonist (11)	BMCL (2022) 75:128981
MRS4832	P2Y ₁₄ receptor antagonist (19)	JMC (2023), 66(13):9076
MRS4833	P2Y ₁₄ receptor antagonist (15)	JMC (2023), 66(13):9076
MRS4839	P2Y ₆ receptor antagonist (25)	BMCL (2022) 75:128981
MRS4841	P2Y ₆ receptor antagonist (27) (2b)	BMCL (2022) 75:128981 Cells (2024) 13:1366
MRS4842	P2Y ₆ receptor antagonist (28)	BMCL (2022) 75:128981
MRS4845	P2Y ₁₄ R antag. double prodrug (62) of PPTN	JMC (2023), 66(13):9076
MRS4849	P2Y ₁₄ R antag. carbamate prodrug (61) of PPTN	JMC (2023), 66(13):9076
MRS4853	P2Y ₆ receptor antagonist (26) (14)	BMCL (2022) 75:128981 Cells (2024) 13:1366
MRS4855	P2Y ₁₄ receptor antag. prodrug (50) of MRS4833	JMC (2023), 66(13):9076
MRS4865	P2Y ₁₄ R antag. (glycoconjugate, 7a)	ACSPT (2024) 7(10):3255
MRS4866	P2Y ₁₄ R antag. (glycoconjugate, 7b)	ACSPT (2024) 7(10):3255
MRS4872	P2Y ₁₄ R antag. (glycoconjugate, 8a)	ACSPT (2024) 7(10):3255
MRS4882	P2Y ₁₄ R antag. (glycoconjugate, 10a)	ACSPT (2024) 7(10):3255
MRS4885	P2Y ₁₄ R antag. (glycoconjugate, 10b)	ACSPT (2024) 7(10):3255
MRS4903	P2Y ₁₄ R antag. (glycoconjugate, 11a)	ACSPT (2024) 7(10):3255
MRS4906	P2Y ₁₄ R antag. (glycoconjugate, 10f)	ACSPT (2024) 7(10):3255
MRS4908	P2Y ₁₄ R antag. (glycoconjugate, 10h)	ACSPT (2024) 7(10):3255
MRS4910	P2Y ₁₄ R antag. ester prodrug (49) of MRS4833	JMC (2023), 66(13):9076
MRS4911	P2Y ₁₄ R antag. carbamate prodrug (51) of MRS4833	JMC (2023), 66(13):9076
MRS4914	P2Y ₁₄ R antag. (7)	ACSPT (2025) 8:3126
MRS4916	P2Y ₁₄ R antag. (10)	ACSPT (2025) 8:3126
MRS4917	P2Y ₁₄ R antag. (11)	ACSPT (2025) 8:3126
MRS4918	P2Y ₁₄ R antag. (12)	ACSPT (2025) 8:3126
MRS4940	P2Y ₆ receptor antagonist (30)	Cells (2024) 13:1366
MRS4944	P2Y ₆ receptor antagonist (24)	Cells (2024) 13:1366
MRS4948	P2Y ₆ receptor antagonist (20)	Cells (2024) 13:1366
MRS5024 (LJ1915)	selective A ₃ adenosine antagonist (5d)	BMCL (2009) 17:3733
MRS5025 (LJ1916)	selective A ₃ adenosine antagonist (5e)	BMCL (2009) 17:3733
MRS5042	A _{2B} adenosine receptor agonist, 6-Cl (27)	JMC (2007) 50:1810

MRS5098	A _{2B} adenosine agonist (7)	JMC (2008) 51:2088
MRS5099	A _{2B} adenosine agonist (9)	JMC (2008) 51:2088
MRS5101	A _{2B} selective adenosine agonist (8)	JMC (2008) 51:2088
MRS5127	selective A ₃ adenosine antagonist (8) (33b)	JMC (2012) 36:3 BMCL (2006) 16:596
	[¹²⁵ I]MRS5127	BP (2010) 79:967
MRS5147	selective Br-76 A ₃ adenosine antagonist (35b)	NMB (2009) 23:232 BMCL (2006) 16:596
MRS5151	selective A ₃ adenosine agonist (18a) (6)	BMCL (2008) 18:2813 JMC (2009) 15:3994
MRS5219	biotin-conjugated selective A ₃ adenosine ag. (17a)	JMC (2009) 15:3994
MRS5158	selective A ₃ adenosine allosteric enhancer (11) (12a)	ACSPT (2022) 5(8):625 JMC (2022) 65(22):15238
MRS5190	selective A ₃ adenosine allosteric enhancer (12) (12b)	ACSPT (2022) 5(8):625 JMC (2022) 65(22):15238
MRS5202	N ⁶ -(3-I-Bn)-2-Cl-(N)-methanocarba-A-4'-trunc. (3)	JMC (2016) 59:11006
MRS5206	selective fluorescent A _{2A} agonist (AF488)	NI (2013) 63:42
MRS5216	dendrimeric A ₃ adenosine agonist	PR (2012) 65:338
MRS5218	selective fluorescent (Cy5) A ₃ adenosine agonist	BP (2013) 85:1171
MRS5221	clickable A ₃ adenosine agonist (5)	BMCP (2011) 11:11
MRS5233	triazole-model A ₃ adenosine agonist (3)	BMCP (2011) 11:11
MRS5246	dendrimeric A ₃ adenosine agonist (6)	BMCP (2011) 11:11
MRS5303	quantum dot-immobil. A _{2A} adenosine agonist (13)	JNB (2010) 8:11
MRS5318	amine-functionalized A _{2A} adenosine antagonist (7)	BMCL (2011) 21:2740
MRS5342	clickable A ₃ adenosine agonist (9)	BC (2012) 23:232
MRS5346	selective fluorescent (AF488) A _{2A} AR antagonist (9)	BP (2010) 80:506 BMCL (2011) 21:2740
MRS5347	fluorescent (TAMRA) A _{2A} adenosine antagonist	BMCL (2013) 23:26
MRS5383	dendrimeric selective A _{2A} adenosine antagonist (17)	BMCL (2011) 21:2740
MRS5398	clickable adenosine receptor antagonist (4)	BC (2011) 22:1115
MRS5415	selective A ₃ adenosine agonist (32)	JMC (2012) 36:3
MRS5418	fluorescent (Bodipy) A _{2A} adenosine antagonist (14)	BMCL (2013) 23:26 BMCL (2011) 21:2740
MRS5424	fluorescent A _{2A} receptor agonist (AF532)	JN (2008) 590:36
MRS5425	selective F-18 A _{2A} adenosine antagonist	NMB (2011) 38:897
MRS5449	selective fluorescent (AF488) A ₃ AR antagonist	BP (2012) 83:1552
MRS5474	selective A ₁ adenosine agonist (10)	JMC (2012) 55:8075 NP (2017) 114:101
MRS5474	Enterovirus A71 antiviral (31)	BMCL (2020) 30:127599
MRS5537	truncated mixed A ₁ /A ₃ adenosine agonist (5) (19)	JMC (2012) 55:8075 ACS MCL (2011) 6:626
MRS5543	light switchable adenosine agonist	BC (2014) 25:1847
MRS5621	A _{2A} adenosine agonist, D-His conjugate (42)	JMC (2012) 55:538
MRS5630	gold-immobil. A ₃ adenosine agonist (21b)	PS (2013) 9:183
MRS5655	highly selective A ₃ adenosine agonist (27)	JMC (2012) 55:4847
MRS5657	highly selective A ₃ adenosine ag. (p-F, N ⁶ -Me, 13)	JMC (2012) 55:4847

MRS5661	highly selective A ₃ adenosine ag. (2-pyridyl, 19)	JMC (2014) 57: 9901
	(10)	JMC (2012) 55:4847
MRS5663	highly selective A ₃ adenosine ag. (o-Cl, N ⁶ -Me, 14)	JMC (2012) 55:4847
	(11)	JMC (2014) 57: 9901
MRS5676	mixed A ₃ agonist+dopamine transporter modulator	JPET (2016) 357:24
	(36)	JMC (2016) 59:11006
MRS5678	highly selective A ₃ adenosine ag. (p-F, 28)	JMC (2012) 55:4847
MRS5679	highly selective A ₃ adenosine ag. (biphenyl, 35)	JMC (2012) 55:4847
MRS5697	highly selective A ₃ adenosine ag. (o-Cl, 29)	JMC (2012) 55:4847
MRS5698	highly selective A ₃ adenosine agonist (3,4-F ₂ , 31)	JMC (2012) 55:4847
	(1)	PS (2015) 11:371
		MCC (2015) 6:555
MRS5699	highly selective A ₃ adenosine ag. (p-NH ₂ , 32)	JMC (2012) 55:4847
MRS5700	highly selective A ₃ adenosine ag. (m-COOH, 33)	JMC (2012) 55:4847
MRS5701	selective water soluble A ₁ /A ₃ adenosine agonist (6)	JMC (2013) 56:5949
	(34)	JMC (2012) 55:4847
MRS5728	gold-immobil. A ₁ /A _{2A} adenosine antagonist (26a)	PS (2013) 9:183
MRS5761-MRS5762	A ₃ adenosine antagonists	US 9,227,979 B2
		MCC (2019) 10:1094
MRS5763	selective fluorescent (AF488) A ₃ AR antagonist (23)	EJMC (2020) 186:111886
MRS5776	selective A ₃ adenosine antagonist	JMC (2013) 56:5949
MRS5811-MRS5840	A ₃ adenosine antagonists	US 9,227,979 B2
		MCC (2019) 10:1094
MRS5841	selective water-soluble A ₃ adenosine agonist (7)	JMC (2013) 56:5949
		NP (2017) 114:101
MRS5842	fluorescent (Alexa647) A _{2A} receptor antagonist	JCR (2018) 283:135
MRS5854	A _{2A} adenosine receptor affinity label	ACSML (2014) 5:1043
MRS5861	selective sulfonate hA ₃ adenosine antagonist (16)	JMC (2013) 56:5949
MRS5911	A _{2B} adenosine agonist (originally from IJzerman lab)	BP (2018) 151:201
		DDR (2000) 49:85
MRS5919	selective A ₃ adenosine agonist, 6-CH ₃ (15)	JMC (2016) 59:3249
MRS5923	selective A ₃ adenosine antagonist (8)	PONE (2014) 9:e97858
MRS5930	A ₃ antagonist, an adenine deriv. (1)	JMC (2016) 59:11006
	A ₃ antagonist, α _{2B} adrenergic receptor ligand (9)	PONE (2014) 9:e97858
MRS5942	novel A ₁ /A _{2A} /A ₃ adenosine antagonist (23)	JCIM (2015) 55:550
MRS5969	furan-2-yl-ethynyl selective A ₃ adenosine ag. (27)	JMC (2014) 57: 9901
MRS5975	c-hexylethynyl selective A ₃ adenosine agonist (38)	JMC (2014) 57: 9901
MRS5976	c-propylethynyl selective A ₃ adenosine agonist (37)	JMC (2014) 57: 9901
MRS5979	ferrocene-containing A ₃ adenosine agonist (36)	JMC (2014) 57: 9901
	(4)	MCC (2015) 6:555
MRS5980	highly selective A ₃ adenosine agonist (33)	JMC (2014) 57: 9901
	(10)	ACSMCL (2015) 6:804
	(39)	JMC (2016) 59:11006
	(2)	MCC (2015) 6:555
MRS7110	selective A ₃ adenosine agonist (5)	MCC (2015) 6:555
MRS7111	selective A ₃ adenosine agonist (2-triazole) (23)	ACSMCL (2015) 6:804

MRS7116	selective A ₃ adenosine agonist (9)	MCC (2015) 6:555
MRS7126	selective A ₃ adenosine agonist (15)	MCC (2015) 6:555
MRS7134	h5-HT _{2B} methanocarba antagonist/A ₁ agonist (14)	JMC (2016) 59:11006
MRS7135	selective A ₃ adenosine agonist (11)	ACSMCL (2015) 6:804
MRS7137	selective A ₃ adenosine agonist (16)	MCC (2015) 6:555
MRS7138	selective A ₃ adenosine agonist (17)	MCC (2015) 6:555
MRS7139	selective A ₃ adenosine agonist (18)	MCC (2015) 6:555
MRS7140	selective A ₃ adenosine agonist (19)	ACSMCL (2015) 6:804
MRS7144	selective A ₃ adenosine agonist (20)	ACSMCL (2015) 6:804
MRS7145	photoactivatable A _{2A} receptor antagonist	JCR (2018) 283:135
MRS7146	selective A ₃ adenosine agonist, cPr-me (17)	ACSMCL (2015) 6:804
MRS7151	CHEMBL4079448 selective A ₃ agonist (4'-Se-Cl-IB-MECA, 3p)	JMC (2017) 60:3422
MRS7154	selective A ₃ adenosine agonist (12)	ACSMCL (2015) 6:804
MRS7156	dopamine transporter allosteric enhancer (59)	EJMC (2026) 301:11867
MRS7158	N ⁶ -diMe-(N)-methanocarba, A ₃ ligand (42)	JMC (2016) 59:11006
MRS7168	novel mixed A ₁ /A ₃ adenosine agonist (14)	ACSCB (2016) 11:2763
MRS7185	h5-HT _{2B} methanocarba antagonist (23)	JMC (2016) 59:11006
MRS7195	selective A ₃ adenosine agonist, 6-CH ₃ (19)	JMC (2016) 59:3249
MRS7202	selective A ₃ adenosine agonist, lacking 6-NH (20)	JMC (2016) 59:3249
MRS7216	tethered A _{2A} adenosine agonist for bone (8a)	ART (2022) 24:265
MRS7220	selective A ₃ adenosine agonist, 6-CH ₃ (21)	JMC (2016) 59:3249
MRS7221	h5-HT _{2B} methanocarba antagonist (26)	JMC (2016) 59:11006
MRS7232	dopamine transporter allosteric modulator (10) (24) (2)	JMC (2017) 60:3109 ACSO (2018) 3:12658 EJMC (2026) 301:11867
MRS7235	N ⁶ -diMe-(N)-methanocarba ester (29), inactive A ₃	JMC (2016) 59:11006
MRS7240	mixed A _{2A/3} adenosine antagonist (36)	SR (2017) 7:6398
MRS7249	N ⁶ -cPr ₂ Me-2-Cl-(N)-methanocarb-A-5'-Pr-ester (27)	JMC (2016) 59:11006
MRS7251	dopamine transporter allosteric modulator (14) (30) (3)	JMC (2017) 60:3109 ACSO (2018) 3:12658 EJMC (2026) 301:11867
MRS7292	dopamine transporter allosteric modulator (9) (15) (27) (1)	JMC (2017) 60:3109 MP (2019) 96:180 EJMC (2022) 231:114103 Nat (2024) 632:672 EJMC (2026) 301:11867
MRS7293	N ⁶ -cPr ₂ Me-2-Cl-(N)-methanocarb-A-5'-Me-ester (25)	JMC (2016) 59:11006
MRS7296	dopamine transporter allosteric modulator, rib. (29)	JMC (2017) 60:3109
MRS7299	κ-opioid antagonist (nucleoside) (28)	ACSO (2018) 3:12658
MRS7304	dopamine transporter allosteric modulator (16) (32) (4)	JMC (2017) 60:3109 ACSO (2018) 3:12658 EJMC (2026) 301:11867
MRS7322	fluorescent (Cy5) A _{2A} receptor antagonist (9)	MCC (2017) 8:1659 Cells (2020) 9:1200
MRS7323	P-gp and ABCG2 inhibitor (8)	MP (2019) 96:180

	(17)	EJMC (2022) 231:114103
	(9)	JMC (2026), 69:4945
MRS7331	κ -opioid antagonist (nucleoside) (39)	ACSO (2018) 3:12658
MRS7334	A ₃ adenosine receptor agonist, K _i 0.28 nM (16)	ACSML (2020) 11:1935
MRS7335	κ -opioid antagonist (nucleoside) (40)	ACSO (2018) 3:12658
MRS7343	κ -opioid partial agonist (nucleoside) (43)	ACSO (2018) 3:12658
MRS7344	photocleavable A ₃ adenosine agonist	PR (2021) 170:105731
MRS7352	sulfonated A _{2A} receptor antagonist (13)	MCC (2017) 8:1659
MRS7358	κ -opioid antagonist (truncated nucleoside) (54)	ACSO (2018) 3:12658
MRS7395	fluorescent (AF647) A _{2A} receptor antagonist (10)	MCC (2017) 8:1659
		Cells (2020) 9:1200
MRS7396	fluorescent (Bodipy) A _{2A} receptor antagonist (11)	MCC (2017) 8:1659
MRS7414	κ -opioid ligand (isopropylidene nucleoside) (77)	ACSO (2018) 3:12658
MRS7416	fluorescent (AF488) A _{2A} receptor antagonist (12)	MCC (2017) 8:1659
MRS7422	A ₃ adenosine agonist (Cl-IB-MECA) prodrug (5)	PS (2020) 16:367
MRS7431	A ₃ adenosine antagonist (2-cPr) in PAM series (17)	JMC (2022) 65(22):15238
	(1)	ACSPT (2022) 5(8):625
MRS7469	A ₁ receptor agonist (9)	JMC (2019) 62:1502
MRS7476	A ₃ adenosine agonist (MRS5698) prodrug (6)	PS (2020) 16:367
MRS7489	A _{2A} adenosine agonist (4)	CS (2021) 12:960
MRS7497	human A ₃ receptor antagonist (adenine deriv., 17)	MCC (2018) 9:1920
MRS7535	fluorescent (Cy7) A ₃ antagonist (19)	PS (2023) 19, 565
MRS7551	selective A ₃ adenosine allosteric enhancer (13)	ACSPT (2022) 5(8):625
	(14)	JMC (2022) 65(22):15238
MRS7591	human and mouse A ₃ receptor partial agonist (15)	JMC (2020) 63:4334
MRS7608	ABCG2 inhibitor (37c)	EJMC (2022) 231:114103
MRS7618	A ₃ adenosine agonist (11)	EJMC (2022) 228:113983
MRS7635	A ₃ adenosine agonist (21)	EJMC (2022) 228:113983
MRS7663	A _{2B} adenosine antagonist, irreversible (29)	BP (2022) 200:115027
MRS7704	Enterovirus A71 antiviral (48)	BMCL (2020) 30:127599
MRS7734	macrocyclic precursor A ₃ adenosine agonist (11)	ACSPT (2023) 6:1288
MRS7735	macrocyclic A ₃ adenosine agonist (12)	ACSPT (2023) 6:1288
MRS7753	Hsp90 (Grp94) inhib. and adenosine agonist (33)	ACSMCL (2021) 12:373
MRS7774	Fluorescent (JF646) A _{2A} antagonist (12)	PS (2023) 19, 565
MRS7787	photoswitchable A ₃ receptor agonist (4)	JACS (2025) 147:874
MRS7788	selective A ₃ adenosine allosteric enhancer (18)	JMC (2022) 65(22):15238
MRS7792	A ₃ partial agonist, ester, N ⁶ -2-Ph-Et (27)	EJMC (2022) 228:113983
MRS7799	A ₃ adenosine antagonist, DPTN	PS (2021) 17:737
	A ₃ adenosine antagonist, DPTN (9)	ACMCL (2022) 13:623
		ACSPT (2023) 6:1266
[³H]MRS7799	A ₃ adenosine antagonist radioligand	ACMCL (2022) 13:623
MRS7967	A ₃ adenosine allosteric enhancer (35)	JMC (2022) 65(22):15238
MRS7800	ABCG2 inhibitor (64)	EJMC (2022) 231:114103
MRS7816	selective A ₁ adenosine antagonist (22)	CC (2021) 57:12305
MRS7827	selective A ₃ adenosine allosteric enhancer (7)	ACSPT (2022) 5(8):625
	(20)	JMC (2022) 65(22):15238

MRS7907	A ₃ adenosine antagonist (16d)	ACMCL (2022) 13:623 ACSPT (2023) 6:1266 EJMC (2023) 259:115691
MRS7925	h5-HT _{2B} methanocarba antagonist (43)	ACMCL (2023) 14(12):1640
MRS7932	selective A ₁ adenosine allosteric enhancer (21)	ACMCL (2023) 14(12):1640
MRS7935	selective A ₁ adenosine allosteric enhancer (15)	ACMCL (2023) 14(12):1640
MRS7944	selective A ₁ adenosine allosteric enhancer (12)	JMC (2022) 65(22):15238
MRS7965	selective A ₃ adenosine allosteric enhancer (27)	ACSPT (2024), 7:2154
MRS8028	selective A ₃ adenosine ag., 2-aryl (23)	ACSPT (2024), 7:2154
MRS8030	selective A ₃ adenosine ag., 2-phenyl (9)	ACSPT (2024), 7:2154
MRS8031	high efficacy, selective A ₃ adenosine ag. (19)	ACSPT (2024), 7:2154
MRS8032	high efficacy, selective A ₃ adenosine ag. (10)	ACSPT (2024), 7:2154
MRS8033	macrocyclic A ₃ adenosine agonist (19)	ACSPT (2023) 6:1288
MRS8034	high efficacy, selective A ₃ adenosine ag. (14)	ACSPT (2024), 7:2154
MRS8035	macrocyclic precursor A ₃ adenosine agonist (18)	ACSPT (2023) 6:1288
MRS8039	high efficacy, selective A ₃ adenosine ag. (11)	ACSPT (2024), 7:2154
MRS8041	selective A ₃ adenosine ag. (o-Cl, N ⁶ -Et, 3b)	ACSPT (2024), 7:2154
MRS8042	selective A ₃ adenosine ag., 2-aryl (34)	ACSPT (2024), 7:2154
MRS8054	selective A ₃ adenosine allosteric enhancer (39)	JMC (2022) 65(22):15238
MRS8062	high efficacy, selective A ₃ adenosine ag. (31)	ACSPT (2024), 7:2154
MRS8063	high efficacy, selective A ₃ adenosine ag. (26)	ACSPT (2024), 7:2154
MRS8072	h5-HT _{2B} methanocarba antagonist (35)	JMC (2024), 67:21264
MRS8074	A ₃ adenosine antagonist (19)	ACMCL (2022) 13:623
MRS8099	h5-HT _{2B} methanocarba antagonist (45)	EJMC (2023) 259:115691
MRS8100	h5-HT _{2B} methanocarba antagonist (37)	JMC (2024), 67:21264
MRS8134	h5-HT _{2B} methanocarba antagonist (48)	EJMC (2023) 259:115691
MRS8142	h5-HT _{2B} methanocarba antagonist (27)	JMC (2024) 67:21264
MRS8201	Dual h5-HT _{2B} /5-HT _{2C} methanocarba antag. (46)	JMC (2024) 67:21264
MRS8209	h5-HT _{2B} methanocarba antagonist (40)	JMC (2024) 67:21264
MRS8247	selective A ₃ adenosine PAM (alkyne-C8, 26)	JMC (2024) 67(14):12221
MRS8265	selective A ₃ adenosine PAM (C10, 17)	JMC (2024) 67(14):12221
MRS8278B	selective A ₃ adenosine PAM (N1-benzyl, 53)	JMC (2024) 67(14):12221
MRS8279	selective A ₃ adenosine PAM (alkyne-C9, Me ₂ N 36)	JMC (2024) 67(14):12221
MRS8288	dual P-gp and ABCG2 inhibitor (16)	JMC (2026), 69:4945
MRS8300	ABCG2 inhibitor (22)	JMC (2026), 69:4945
MRS8304	selective A ₃ adenosine PAM (alkyne-C7, 25)	JMC (2024) 67(14):12221
MRS8308	selective A ₃ adenosine PAM (alkyne-C9, 27)	JMC (2024) 67(14):12221
	(15)	JMC (2025) 68:20717
MRS8315	selective A ₃ adenosine PAM (C4+C8 diamine, 41)	JMC (2024) 67(14):12221
MRS8339	selective A ₃ adenosine PAM (piperidine, 45)	JMC (2024) 67(14):12221
MRS8340	selective A ₃ adenosine PAM (piperazine, 46)	JMC (2024) 67(14):12221
MRS8343	selective A ₃ adenosine PAM (pyrrolidine, 44)	JMC (2024) 67(14):12221
MRS8351	dopamine/norepi transporter allosteric inhibitor (56)	EJMC (2026), 301:11867
MRS8365	potent ABCG2 inhibitor (39)	JMC (2026), 69:4945
MRS8392	dopamine/norepi transporter allosteric inhibitor (11)	EJMC (2026), 301:11867
MRS8395	dopamine transporter allosteric enhancer (9)	EJMC (2026), 301:11867
MRS8396	monoamine transporter allosteric inhibitor (23)	EJMC (2026), 301:11867

MRS8419	monoamine transporter allosteric inhibitor (24)	EJMC (2026), 301:11867
MRS8406	dopamine transporter allosteric enhancer (44)	EJMC (2026), 301:11867
MRS8430	ABCG2 ATPase activator (47)	JMC (2026), 69:4945
MRS8431	ABCG2 inhibitor (30)	JMC (2026), 69:4945
MRS8432	potent ABCG2 ATPase activator (40)	JMC (2026), 69:4945
MRS8433	selective A ₃ adenosine ago-PAM (N1-Bn, C9, 33)	JMC (2025) 68:20717
MRS8435	selective A ₃ PAM (N1-Bn, alkyne-C9, Ac-pip, 38)	JMC (2025) 68:20717
MRS8451	DAT/NET bitopic allosteric inhibitor (31)	EJMC (2026) 301:11867
MRS8453	selective A ₃ adenosine PAM (N1-Bn(Me), 10)	JMC (2025) 68:20717
MRS8454	selective A ₃ PAM (N1-Bn, alkyne-C9, piperid, 35)	JMC (2025) 68:20717
MRS8455	dopamine transporter allosteric inhibitor (54)	EJMC (2026) 301:11867
MRS8456	monoamine transporter allosteric tri-inhibitor (53)	EJMC (2026) 301:11867
MRS8458	fluorescent A ₃ adenosine PAM (BODIPY-TR), 22)	JMC (2025) 68:20717
MRS8460	selective A ₃ PAM (N1-Bn, alkyne-C8, 29)	JMC (2025) 68:20717
MRS8461	dopamine transporter allosteric inhibitor (17)	EJMC (2026) 301:11867
MRS8463	selective A ₃ PAM (N1-Bn, alkyne-C8, Ac-pip, 31)	JMC (2025) 68:20717
MRS8469	select. A ₃ PAM (N1-Bn(Me), alkyne-C9, piperid, 36)	JMC (2025) 68:20717
MRS8473	selective A ₃ PAM (N1-Bn, alkyne-C9, piperid., 34)	JMC (2025) 68:20717
MRS8475	selective caged A ₃ PAM (NVOc, alkyne-C9, 17)	JMC (2025) 68:20717
MRS8484	selective A ₃ PAM (N1-Bn, alkyne-C9, Gly-pip, 42)	JMC (2025) 68:20717
MRS8514	select. A ₃ PAM (N1-Bn(I), alkyne-C9, piperid, 46)	JMC (2025) 68:20717
MRS8520	fluorescent A ₃ adenosine PAM (rhodamine B, 40)	JMC (2025) 68:20717
MRS8564	SERT allosteric inhibitor	unpublished
NCK33	polo-box domain, Polo-like kinase1 inhibitor (79)	JMC (2020) 63:14087
NCK100	polo-box domain, Polo-like kinase1 inhibitor (143)	JMC (2020) 63:14087
NCK106	polo-box domain, Polo-like kinase1 inhibitor (145)	JMC (2020) 63:14087
NCK103	PBD, Polo-like kinase1 inhibitor (15)	ACSPT (2023) 6(3):422
NCK149	PBD, Polo-like kinase1 inhibitor (43)	ACSPT (2023) 6(3):422
NCK167	PBD, Polo-like kinase1 inhibitor prodrug (78)	ACSPT (2023) 6(3):422
NCK173	PBD, Polo-like kinase1 inhibitor prodrug (80)	ACSPT (2023) 6(3):422
NCK189	PBD, Polo-like kinase1 inhibitor, Allopole-A (3)	PNAS (2023) 120:e2305037120
NCK190	PBD, Plk1 inhibitor prodrug, Allopole (4)	PNAS (2023) 120:e2305037120
NCK195	PBD, Polo-like kinase1 inhibitor, biotin conj. (22)	PNAS (2023) 120:e2305037120
NECA N1-oxide	potent, nonselective adenosine agonist (29)	MP (1994) 45:1101
NECI	inosine-related A ₃ adenosine (53)	MP (1994) 45:1101
PAPA-APEC	selective A _{2A} adenosine agonist, to radioiodinate*	PNAS (1989) 86:6572
PAPA-TAC	M ₁ muscarinic antagonist (6)	MP (1991) 40:639
PAPA-XAC	A ₁ adenosine antagonist, to radioiodinate	BC (1992) 3:234
PAPA-XAC-SANPAH	A ₁ radioiodinated photoaffinity label	MP (1987) 32:184
PAPET-ATP	potent P _{2Y} ₁ , P _{2X} ₁ and P _{2X} ₃ agonist (16)	FL (1989) 257:292
	(15)	JMC (2002) 45:4057
		JMC (1993) 36:3937
		DDR (2000) 49:253
PPTN	selective P _{2Y} ₁₄ receptor antagonist	MP (2013) 84:41
	(5)	BMCL (2015) 25:4733
	(2b)	JMC (2023), 66(13):9076

PPTN (tritiated)	radiolabeled P2Y ₁₄ receptor antagonist	JMC (2020) 63:9563
SPA	water-soluble, selective A ₁ adenosine agonist*	JMC (1992) 35:4143 NP (2017) 114:101
SVP333	selective P2Y ₂ allosteric partial agonist (7c)	BMC (2012) 20:2304
TAC	amine congener, muscarinic antagonist*	BC (1992) 3:234
TEMPO-APEC	spin labeled A _{2A} adenosine agonist (15)	JMR (1989) 32:1043
TEMPO-XAC	spin labeled A ₁ /A _{2A} adenosine antagonist	BP (1987) 36:1697
4'-thio-CI-IB-MECA		
(LJ-529)	selective A ₃ adenosine agonist	JMC (2006) 49:273
2-thio-UTP	selective P2Y ₂ receptor agonist	BP (2006) 71:540
α-thiophosphates (Rp or Sp) of various uracil and adenine nucleotides		
	selective P2Y _{6R} or P2Y _{14R} or other P2R agonists	NC (2024) 16:249
XAC	potent, nonselective adenosine antagonist	PNAS (1985) 28:1334 ACSPT (2023) 6:1266 NI (1991) 18:207 NL (1988) 86:121 PNAS (1986) 83:4089 FL (1989) 257:292
	[³ H]XAC	JMC (1985) 28:1334
	XAC on solid support (Affi-gel-10)	MP (2003) 63:1021
XCC	potent, A ₁ selective adenosine antagonist	MP (2001) 60:1057
VUF5455	selective A ₃ adenosine allosteric enhancer	MCC (2019) 10:1094
VUF8504	selective A ₃ adenosine allosteric enhancer	AC (2019) 91:8162
WS98	fluorescent (fluorescein) A _{2A} AR antagonist (15)	AC (2019) 91:8162
3288	A _{2A} receptor antagonist from mass spec screen	AC (2019) 91:8162
3588	A _{2A} receptor antagonist from mass spec screen	AC (2019) 91:8162
3676	A _{2A} receptor antagonist from mass spec screen	AC (2019) 91:8162

* Available through the NIMH synthesis program

(<http://nimh-repository.rti.org/>)

** journal abbreviation: EJMC, European Journal of Medicinal Chemistry; FL, FEBS Lett.; JANS, J. Autonom. Nerv. Syst.; JCIM, J. Chem. Inf. Modeling; JF, Journal of Fluorescence; JMC, Journal of Medicinal Chemistry; JMR, Journal of Molecular Recognition; JN, Journal of Neurochemistry; JPET, J. Pharmacol. Exp. Ther.; BJP, Br. J. Pharmacol.; BP, Biochemical Pharmacology; BC, Bioconjugate Chemistry; DDR, Drug Devel. Res.; EER, Exp. Eye Res.; MCC, Med Chem Comm; MP, Molecular Pharmacology; NI, Neurochem. Int.; NL, Neurosci. Lett.; NMB, Nucl. Med. Biol.; NP, Neuropharmacology; OBC, Org. Biomol. Chem.; OL, Organic Lett.; PNAS, Proceedings of the National Academy of Sciences; BMC, Bioorganic and Medicinal Chemistry; BMCL, Bioorganic and Medicinal Chemistry Letters; BMCP, Biomed Central Pharmacol.; ACSCB, ACS Chemical Biology; ACSML, ACS Medicinal Chemistry Letters; ACSN, ACS Chemical Neuroscience; ACS Omega, ACSO; CCC, Coll. Czech. Chem. Comm.; JTH, J. Thromb. Haemost.; PR, Pharmacol. Res.; PR, Pharmacological Research; PS, Purinergic Signalling; PONE, PLoS ONE; RSCA, RSC Advances; SR, Scientific Reports; TIPS, Trends Pharmacol. Sci.; JCR, J. Controlled Release; AC, Analytical Chemistry; CS, Chemical Science; BIOM, Biomolecules; ACSPT, ACS Pharmacology and Translational Science; ART, Arthritis Research and Therapy; US, US patent; NC, Nature Chemistry; Nat, Nature; JACS, J. Am. Chem. Soc.; CB, Communications Biology; ANG, Angewandte Chemie Int. Ed.

See: Millipore-Sigma; Tocris; MedChemExpress; NIMH Synth. Progr. (CSDSP) for availability. Many other compounds not listed here are available from MedKoo, <https://medkoo.com/>; Glix Labs, Inc., <http://www.glixlabs.com>

First 19 pages of PubChem “MRS” listings:

Name	PubChem IDs	CHEMBL	CAS registry no.
IB-MECA	123683		152918-18-8
Cl-IB-MECA	3035850		163042-96-4
AB-MECA	5310992		
I-AB-MECA	9958472	133566	152918-27-9
[¹²⁵ I] I-AB-MECA	73754993		
LUF6000	11711282		
ADAC	2026 , 126054 , 23789715		
TEMPO-ADAC	131718190		
ADAC-NCS	131718368		
APEC	3081741		
PAPA-APEC	3081715		
¹²⁵ I-AZIDO-PAPA-APEC	3083135		
p-DITC-APEC	3037834		
FITC-APEC	23772170		
m-DITC-XAC	3082962		
ED-p-DITC-XAC	3082963		
FM101	16735504		945457-84-1
XAC	5697		
[³ H]XAC	5697		
XAC-BY630	73755041		
XCC	126079		
PPTN (TFA salt)	132470894		
PPTN (tritiated)	158999167		
VUF5455	10339071		
VUF8504	10247610		
MRS923	631105		
MRS1041	10247549		
MRS1042	10500941		
MRS1062	18784677		
MRS1063	10764269		
MRS1065	10710647		
MRS1066	10806465		
MRS1067	252716		
MRS1072	10613570		
MRS1084	10593671		
MRS1086	10813088		
MRS1088	252696		
MRS1089	44365732		
MRS1093	10568125		

MRS1131	248021		
MRS1132	736736		
MRS1177	10045876		
MRS1186	10065929		
MRS1191	393594, 10028016		
MRS1204	14484978		
MRS1220	393595		
MRS1292	10369458		
MRS1334	4519822, 6604859		
MRS1476	9885773		
MRS1477	9843337		
MRS1486	9843120		
MRS1505	9802941		
MRS1523	3661570	CHEMBL111545	212329-37-8
MRS1595	9936058		
MRS1702	101024759		
MRS1703	10383636		
MRS1704	10065211		
MRS1705	10318342		
MRS1706	5139184		
MRS1740	102008056		
MRS1741	102008057		
MRS1751	10345002		
MRS1752	10407106		
MRS1753	10252532		
MRS1754	71311720, 6603931		
MRS1845	11538542	CHEMBL1256776	544478-19-5
MRS1898	44354130, 9850648		
MRS1939	44359364		
MRS1941	135996022		
MRS1957	135996021		
MRS1971	44313794		
MRS1997	135996023		
MRS1998	44313377		
MRS2159	135419189, 135484644		
	5052387		
MRS2160	135539037		
MRS2179	90479745,		
	24867852, 49797715		
	5311303, 5311302		
	71308613, 52944044		
MRS2191	135507286		
MRS2209	10455067		
MRS2211	136068412		
MRS2216	10321986		
MRS2217	10743016		

MRS2219	3960826		
MRS2233	10763892		
MRS2248	10789219		
MRS2255	10251798		
MRS2257	136094862 , 136016331		
MRS2264	10026444		
MRS2268	44353637		
MRS2271	102371548		
MRS2267	10070925		
MRS2269	10505783		
MRS2279	9847505 , 90488744		
MRS2283	10005091		
MRS2286	9955181		
MRS2298	10432920		
MRS2306	44446327		
MRS2339	11069215		
MRS2346	10450691		
MRS2351	136171345		
MRS2365	74989267 , 146158891		
	10907003 , 131700247		
	90488743		
MRS2379	135996025		
MRS2395	10071919		
MRS2396	44313671		
MRS2398	135996024		
MRS2427	44446290		
MRS2447	25032957		
MRS2481	10073262		
MRS2485	11325278		
MRS2496	10894633		
MRS2500	90488745 , 44448831		
	146159735		
MRS2554	44446300		
MRS2567	11266452		
MRS2578	16078986	CHEMBL1321988	711019-86-2
MRS2603	135545444		
MRS2633	11494976		
MRS2950	73755158		
MRS2693	90488768 , 44415771		
MRS2670	16220889		
MRS2690	73755042 , 44422870		
	145710424 , 145711047		
MRS2695	16007361		
MRS2698	16116566		
MRS2732	44585518		
MRS2738	46226460		

MRS2768 [90488893](#),
[126455894](#), [44585514](#)

MRS2775 [46229287](#)

MRS2782 [44585949](#)

MRS2802 [91827349](#)

MRS2820 [46226445](#)

MRS2825 [24858471](#)

MRS2905 [121513874](#)

MRS2925 [45379079](#)

MRS2927 [53262904](#)

MRS2935 [46229291](#)

MRS2957 [91827347](#)

MRS2964 [46831685](#) CHEMBL1084612, CHEMBL1198872

MRS2978 [53354748](#)

MRS3057 [16087946](#)

MRS3165 [101334759](#)

MRS3310 (CI-936)
[10388920](#)

MRS3412 [44410673](#)

MRS3481 [11584486](#)

MRS3558 [11248240](#), [45483955](#)

MRS3625 [44589867](#)

MRS3642 (LJ-1256)
[16656768](#)

MRS3718 [11618723](#)

MRS3771 [11678491](#)

MRS3775 [53394567](#)

MRS3777 [56972200](#), [11771279](#)

MRS3820 (LJ-1251)
[16220189](#)

MRS3854 [16203540](#)

MRS3997 [16203542](#) (CAS Reg. no. 936252-34-5)

MRS4062 [53262902](#)

MRS4074 [71562889](#)

MRS4084 [71562888](#)

MRS4174 [124221650](#)

MRS4183 [124221652](#)

MRS4458 [134611895](#)

MRS4478 [134611896](#)

MRS4552 [146397156](#)

MRS4574 [139392135](#)

MRS4596 [165413190](#)

MRS4597 (o-Cl)
[146397177](#)

MRS4598 [164946892](#), [146397174](#)
[162639258](#)

MRS4601 (p-CF₃)
[153405662](#)

MRS4608 [139392013](#)

MRS4618 (p-Br)
[146397175](#)

MRS4620 [146397173](#), [163322134](#)

MRS4621 (p-F)
[146397176](#)

MRS4625 [155817521](#), [155770281](#)

MRS4639 [164585457](#)

MRS4640 [164585579](#)

MRS4645 (p-CH₃)
[146397273](#)

MRS4654 [164585602](#)

MRS4693 [139406761](#)

MRS4695 (Me₃Si)
[164614469](#)

MRS4719 [165413190](#)

MRS4738 [163322040](#)

MRS4748 (**38** in Wen et al., 2022)
[164585647](#)

MRS4774 (Et₃Si P2Y₆ antag)
[164628974](#)

MRS4815 [164946890](#)

MRS4825 [164585343](#)

MRS4832 [172684313](#)

MRS4833 [171378581](#)

MRS4853 [171357206](#)

MRS5049 (3,5-di-F-Ph)
[44572478](#)

MRS5098 [24827415](#)

MRS5099 [24827417](#)

MRS5100 [24827290](#)

MRS5101 [24827289](#)

MRS5127 [44579714](#)

MRS5128 [44449141](#)

MRS5147 [44579716](#)

MRS5151 [44232535](#)

MRS5166 [44448982](#)

MRS5190 (2-adamantyl, A₃ PAM)
[44572609](#)

MRS5346 [70680953](#)

MRS5418 [54587624](#)

MRS5424 [102310155](#)

MRS5464 [70695811](#)

MRS5474 [70695812](#)

MRS5679 [57523251](#)
MRS5698 [57523213](#)
MRS5701 [102529275](#)
MRS5704 [57523252](#)
MRS5762 89700960
MRS5763 118629501
MRS5811 134155693
MRS5812 134132496
MRS5813 134144876
MRS5814 134136933
MRS5815 134151288
MRS5816 89701208
MRS5817 71656727
MRS5818 134157535
MRS5819 134145271
MRS5820 134148087
MRS5821 134151252
MRS5822 89700964
MRS5824 134132827
MRS5825 89701237
MRS5826 71656728
MRS5838 89701152
MRS5840 89701143
MRS5841 [71764235](#), [102529276](#)
MRS5980 [118730351](#)
MRS7292 [167312205](#), [137633601](#)
MRS7469 [137553161](#)
MRS7788 [167312259](#)
MRS7799 [22282339](#)
MRS7907 [166633518](#)
MRS7967 [168286277](#)
MRS8028 [171714393](#)
MRS8054 [166176970](#), [478109837](#)
MRS8209 [172676966](#)
MRS8247 [172419450](#)

CHEMBL2181976
CHEMBL5086258